Hyun Jung Lee1, Jae Hyun Kim1,2, Seung Won Kim1,2,3, Hyun Ah Joo4, Hye Won Lee1, You Sun Kim5, Soo Jung Park1, Sung Pil Hong1, Tae Il Kim1, Won Ho Kim1, Young-Ho Kim6, Jae Hee Cheon7,8,9. 1. Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea. 2. Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. 3. Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea. 4. Department of Biochemistry, Yonsei University, Seoul, Korea. 5. Department of Internal Medicine, Inje University College of Medicine, Seoul, Korea. 6. Department of Medicine, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, 135-710, Republic of Korea. younghokim@skku.edu. 7. Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea. GENIUSHEE@yuhs.ac. 8. Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. GENIUSHEE@yuhs.ac. 9. Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea. GENIUSHEE@yuhs.ac.
Abstract
BACKGROUND/AIMS: Data regarding biomarkers to understand disease pathogenesis and to assess disease activity of intestinal Behçet's disease (BD) are limited. Therefore, we aimed to investigate the differentially expressed proteins in sera from patients with intestinal BD and to search for biomarkers using mass spectrometry-based proteomic analysis. METHODS: Serum samples were pooled for the screening study, and two-dimensional electrophoresis (2-DE) was performed to characterize the proteins present in intestinal BD patients. Candidate protein spots were identified using matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF MS) and bioinformatic analysis. To validate the proteomic results, serum samples from an independent cohort were assessed by enzyme-linked immunosorbent assay. RESULTS: Pooled serum samples were used for 2-DE, and approximately 400 protein spots were detected in the sera of intestinal BD patients. Of the 22 differentially expressed proteins, 3 were successfully identified using MALDI-TOF/TOF MS. The three up-regulated proteins identified in the intestinal BD group included fibrin, apolipoprotein A-IV, and serum amyloid A (SAA). Serum SAA in intestinal BD patients (2.76 ± 2.50 ng/ml) was significantly higher than that in controls (1.68 ± 0.90 ng/ml, p = 0.007), which is consistent with the proteomic results. In addition, the level of IL-1β in patients with intestinal BD (8.96 ± 1.23 pg/ml) was higher than that in controls (5.40 ± 0.15 pg/ml, p = 0.009). SAA released by HT-29 cells was markedly increased by tumor necrosis factor-α (TNF-α) and lipopolysaccharides stimulation. CONCLUSIONS: Our proteomic analysis revealed that SAA was up-regulated in intestinal BD patients.
BACKGROUND/AIMS: Data regarding biomarkers to understand disease pathogenesis and to assess disease activity of intestinal Behçet's disease (BD) are limited. Therefore, we aimed to investigate the differentially expressed proteins in sera from patients with intestinal BD and to search for biomarkers using mass spectrometry-based proteomic analysis. METHODS: Serum samples were pooled for the screening study, and two-dimensional electrophoresis (2-DE) was performed to characterize the proteins present in intestinal BD patients. Candidate protein spots were identified using matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF MS) and bioinformatic analysis. To validate the proteomic results, serum samples from an independent cohort were assessed by enzyme-linked immunosorbent assay. RESULTS: Pooled serum samples were used for 2-DE, and approximately 400 protein spots were detected in the sera of intestinal BD patients. Of the 22 differentially expressed proteins, 3 were successfully identified using MALDI-TOF/TOF MS. The three up-regulated proteins identified in the intestinal BD group included fibrin, apolipoprotein A-IV, and serum amyloid A (SAA). Serum SAA in intestinal BD patients (2.76 ± 2.50 ng/ml) was significantly higher than that in controls (1.68 ± 0.90 ng/ml, p = 0.007), which is consistent with the proteomic results. In addition, the level of IL-1β in patients with intestinal BD (8.96 ± 1.23 pg/ml) was higher than that in controls (5.40 ± 0.15 pg/ml, p = 0.009). SAA released by HT-29 cells was markedly increased by tumor necrosis factor-α (TNF-α) and lipopolysaccharides stimulation. CONCLUSIONS: Our proteomic analysis revealed that SAA was up-regulated in intestinal BD patients.
Entities:
Keywords:
Biomarkers; Intestinal Behçet’s disease; Proteomics; Serum amyloid A
Authors: Uli C Broedl; Veronika Schachinger; Arno Lingenhel; Michael Lehrke; Renee Stark; Frank Seibold; Burkhard Göke; Florian Kronenberg; Klaus G Parhofer; Astrid Konrad-Zerna Journal: Inflamm Bowel Dis Date: 2007-04 Impact factor: 5.325
Authors: Paolo Nanni; Fredrik Levander; Giulia Roda; Alessandra Caponi; Peter James; Aldo Roda Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2009-08-07 Impact factor: 3.205
Authors: Thorsten Vowinkel; Mikiji Mori; Christian F Krieglstein; Janice Russell; Fumito Saijo; Sulaiman Bharwani; Richard H Turnage; W Sean Davidson; Patrick Tso; D Neil Granger; Theodore J Kalogeris Journal: J Clin Invest Date: 2004-07 Impact factor: 14.808
Authors: Charles G Knutson; Aswin Mangerich; Yu Zeng; Arkadiusz R Raczynski; Rosa G Liberman; Pilsoo Kang; Wenjie Ye; Erin G Prestwich; Kun Lu; John S Wishnok; Joshua R Korzenik; Gerald N Wogan; James G Fox; Peter C Dedon; Steven R Tannenbaum Journal: Proc Natl Acad Sci U S A Date: 2013-06-10 Impact factor: 11.205
Authors: Yong Gil Hwang; Goundappa K Balasubramani; Ilinca D Metes; Marc C Levesque; S Louis Bridges; Larry W Moreland Journal: Arthritis Res Ther Date: 2016-05-17 Impact factor: 5.156